Jefferies Group LLC Vertex Pharmaceuticals Inc Transaction History

Jefferies Group LLC

$10.2 Billion
Q3 2022

A detailed history of Jefferies Group LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Jefferies Group LLC holds 1,447 shares of VRTX stock, worth $680,495. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,447

Previous 1,116 29.66%

Holding current value

$680,495

Previous $314,000 33.12%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Sep 21, 2023	BUY	$273.83 - $305.53 $90,637 - $101,130	331 Added 29.66%	1,447 $418,000
Q3 2022 Nov 14, 2022	SELL	$273.83 - $305.53 $700,730 - $781,851	-2,559 Reduced 57.69%	1,877 $423,000
Q2 2022 Sep 21, 2023	BUY	$234.96 - $292.55 $85,995 - $107,073	366 Added 48.8%	1,116 $314,000
Q2 2022 Aug 15, 2022	SELL	$234.96 - $292.55 $181,859 - $226,433	-774 Reduced 14.86%	4,436 $336,000
Q1 2022 Sep 21, 2023	SELL	$221.42 - $260.97 $913,357 - $1.08 Million	-4,125 Reduced 84.62%	750 $195,000

Q1 2022 May 16, 2022	SELL	$221.42 - $260.97 $118,238 - $139,357	-534 Reduced 9.3%	5,210 $241,000
Q4 2021 Sep 21, 2023	SELL	$177.01 - $223.45 $3.57 Million - $4.51 Million	-20,191 Reduced 80.55%	4,875 $1.07 Million
Q4 2021 Feb 14, 2022	SELL	$177.01 - $223.45 $3.42 Million - $4.32 Million	-19,322 Reduced 77.08%	5,744 $1.16 Million
Q3 2021 Sep 21, 2023	BUY	$181.39 - $202.99 $1.53 Million - $1.71 Million	8,427 Added 50.65%	25,066 $4.55 Million
Q3 2021 Nov 15, 2021	BUY	$181.39 - $202.99 $1.53 Million - $1.71 Million	8,427 Added 50.65%	25,066 $4.55 Million
Q2 2021 Sep 21, 2023	BUY	$187.49 - $221.1 $1.3 Million - $1.54 Million	6,945 Added 71.64%	16,639 $3.35 Million
Q2 2021 Aug 16, 2021	BUY	$187.49 - $221.1 $1.3 Million - $1.54 Million	6,945 Added 71.64%	16,639 $3.36 Million
Q1 2021 Sep 21, 2023	BUY	$207.02 - $241.31 $1.82 Million - $2.12 Million	8,772 Added 951.41%	9,694 $2.08 Million
Q1 2021 May 14, 2021	BUY	$207.02 - $241.31 $1.82 Million - $2.12 Million	8,772 Added 951.41%	9,694 $2.08 Million
Q4 2020 Sep 21, 2023	SELL	$207.01 - $276.09 $197,694 - $263,665	-955 Reduced 50.88%	922 $217,000
Q4 2020 Feb 16, 2021	BUY	$207.01 - $276.09 $32,707 - $43,622	158 Added 20.68%	922 $218,000
Q3 2020 Nov 13, 2020	SELL	$255.65 - $303.1 $51,641 - $61,226	-202 Reduced 20.91%	764 $208,000
Q1 2020 May 15, 2020	SELL	$199.77 - $247.81 $3.32 Million - $4.12 Million	-16,614 Reduced 94.51%	966 $230,000
Q4 2019 Feb 13, 2020	SELL	$166.71 - $223.91 $3.49 Million - $4.69 Million	-20,944 Reduced 54.37%	17,580 $3.85 Million
Q3 2019 Nov 13, 2019	BUY	$166.23 - $187.09 $3.93 Million - $4.42 Million	23,646 Added 158.93%	38,524 $6.53 Million
Q2 2019 Aug 14, 2019	BUY	$164.61 - $190.37 $1.54 Million - $1.79 Million	9,385 Added 170.85%	14,878 $2.73 Million
Q1 2019 May 15, 2019	BUY	$163.73 - $194.7 $495,119 - $588,772	3,024 Added 122.48%	5,493 $1.01 Million
Q4 2018 Feb 14, 2019	SELL	$151.91 - $192.21 $184,874 - $233,919	-1,217 Reduced 33.02%	2,469 $409,000
Q3 2018 Nov 14, 2018	SELL	$167.73 - $192.74 $6.47 Million - $7.44 Million	-38,586 Reduced 91.28%	3,686 $710,000
Q2 2018 Aug 14, 2018	BUY	$145.72 - $169.96 $1.92 Million - $2.24 Million	13,178 Added 45.29%	42,272 $7.19 Million
Q1 2018 May 15, 2018	BUY	$151.6 - $177.13 $4.39 Million - $5.13 Million	28,940 Added 18792.21%	29,094 $4.74 Million
Q4 2017 Feb 14, 2018	SELL	$137.28 - $155.55 $4.69 Million - $5.31 Million	-34,146 Reduced 99.55%	154 $23,000
Q3 2017 Nov 14, 2017	BUY	$148.13 - $162.24 $5.08 Million - $5.56 Million	34,300	34,300 $5.22 Million

Others Institutions Holding VRTX

# of Institutions

1,624

Shares Held

222M

Call Options Held

1.35M

Put Options Held

1.49M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $121B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jefferies Group LLC with notifications on news.

Account

Jefferies Group LLC Vertex Pharmaceuticals Inc Transaction History